Antiamyloid drugs clear amyloid plaques and modestly slow cognitive decline in patients with Alzheimer’s disease, but whether ...

TOKYO, Jul 16, 2025 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the drug discovery research for Lecanemab (product name: "LEQEMBI"), a ...

Drugs that target amyloid beta proteins in the brain likely have no clinically meaningful positive effects, while increasing the risk of bleeding and swelling in the brain, a new review in the ...

image: Sensitivity-enhanced solid-state NMR spectroscopy can be used in the structural characterization of amyloid β—the pathogenic protein involved in Alzheimer’s disease—as shown by scientists from ...

A new article published in RadioGraphics examines the use of monoclonal antibody therapies for treating Alzheimer's disease and alerts physicians to be on the lookout for a potential side effect: ...

A recent study tests a new drug, gantenerumab on people with a genetically inherited form of Alzheimer’s disease. For people with this condition, dementia is almost inevitable. Gantenerumab helps ...

Share on Pinterest Are anti-amyloid drugs as effective against Alzheimer’s disease as experts had hoped? Image credit: smodj/Getty Images More than 55 million people worldwide are living with ...

Piller is an investigative journalist for Science. In November 2022, Dennis Selkoe, a Harvard professor of neurologic diseases and among the most celebrated and prolific Alzheimer’s researchers, ...

Medications like lecanemab (Leqembi) and donanemab (Kisunla) target amyloid plaques in the brain that build up due to Alzheimer’s disease. They may help slow disease progression for people in the ...